HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.
Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in culture and in infected patients. There is a paucit...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3134476?pdf=render |
| _version_ | 1819069986030747648 |
|---|---|
| author | Geoffrey S Gottlieb Robert A Smith Ndeye Mery Dia Badiane Selly Ba Stephen E Hawes Macoumba Toure Alison K Starling Fatou Traore Fatima Sall Stephen L Cherne Joshua Stern Kim G Wong Paul Lu Moon Kim Dana N Raugi Airin Lam James I Mullins Nancy B Kiviat Papa Salif Sow for the UW-Dakar HIV-2 Study Group |
| author_facet | Geoffrey S Gottlieb Robert A Smith Ndeye Mery Dia Badiane Selly Ba Stephen E Hawes Macoumba Toure Alison K Starling Fatou Traore Fatima Sall Stephen L Cherne Joshua Stern Kim G Wong Paul Lu Moon Kim Dana N Raugi Airin Lam James I Mullins Nancy B Kiviat Papa Salif Sow for the UW-Dakar HIV-2 Study Group |
| author_sort | Geoffrey S Gottlieb |
| collection | DOAJ |
| description | Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in culture and in infected patients. There is a paucity of data on genotypic variation in HIV-2 integrase that might confer intrinsic or transmitted INI resistance.We PCR amplified and analyzed 122 HIV-2 integrase consensus sequences from 39 HIV-2-infected, INI-naive adults in Senegal, West Africa. We assessed genetic variation and canonical mutations known to confer INI-resistance in HIV-1.No amino acid-altering mutations were detected at sites known to be pivotal for INI resistance in HIV-1 (integrase positions 143, 148 and 155). Polymorphisms at several other HIV-1 INI resistance-associated sites were detected at positions 72, 95, 125, 154, 165, 201, 203, and 263 of the HIV-2 integrase protein.Emerging genotypic and phenotypic data suggest that HIV-2 is susceptible to the new class of HIV integrase inhibitors. We hypothesize that intrinsic HIV-2 integrase variation at "secondary" HIV-1 INI-resistance sites may affect the genetic barrier to HIV-2 INI resistance. Further studies will be needed to assess INI efficacy as part of combination antiretroviral therapy in HIV-2-infected patients. |
| first_indexed | 2024-12-21T16:58:45Z |
| format | Article |
| id | doaj.art-e10d00c370c64f6badaf25921dbedff6 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T16:58:45Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e10d00c370c64f6badaf25921dbedff62022-12-21T18:56:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0167e2220410.1371/journal.pone.0022204HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Geoffrey S GottliebRobert A SmithNdeye Mery Dia BadianeSelly BaStephen E HawesMacoumba ToureAlison K StarlingFatou TraoreFatima SallStephen L CherneJoshua SternKim G WongPaul LuMoon KimDana N RaugiAirin LamJames I MullinsNancy B KiviatPapa Salif Sow for the UW-Dakar HIV-2 Study GroupAntiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in culture and in infected patients. There is a paucity of data on genotypic variation in HIV-2 integrase that might confer intrinsic or transmitted INI resistance.We PCR amplified and analyzed 122 HIV-2 integrase consensus sequences from 39 HIV-2-infected, INI-naive adults in Senegal, West Africa. We assessed genetic variation and canonical mutations known to confer INI-resistance in HIV-1.No amino acid-altering mutations were detected at sites known to be pivotal for INI resistance in HIV-1 (integrase positions 143, 148 and 155). Polymorphisms at several other HIV-1 INI resistance-associated sites were detected at positions 72, 95, 125, 154, 165, 201, 203, and 263 of the HIV-2 integrase protein.Emerging genotypic and phenotypic data suggest that HIV-2 is susceptible to the new class of HIV integrase inhibitors. We hypothesize that intrinsic HIV-2 integrase variation at "secondary" HIV-1 INI-resistance sites may affect the genetic barrier to HIV-2 INI resistance. Further studies will be needed to assess INI efficacy as part of combination antiretroviral therapy in HIV-2-infected patients.http://europepmc.org/articles/PMC3134476?pdf=render |
| spellingShingle | Geoffrey S Gottlieb Robert A Smith Ndeye Mery Dia Badiane Selly Ba Stephen E Hawes Macoumba Toure Alison K Starling Fatou Traore Fatima Sall Stephen L Cherne Joshua Stern Kim G Wong Paul Lu Moon Kim Dana N Raugi Airin Lam James I Mullins Nancy B Kiviat Papa Salif Sow for the UW-Dakar HIV-2 Study Group HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. PLoS ONE |
| title | HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. |
| title_full | HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. |
| title_fullStr | HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. |
| title_full_unstemmed | HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. |
| title_short | HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. |
| title_sort | hiv 2 integrase variation in integrase inhibitor naive adults in senegal west africa |
| url | http://europepmc.org/articles/PMC3134476?pdf=render |
| work_keys_str_mv | AT geoffreysgottlieb hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT robertasmith hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT ndeyemerydiabadiane hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT sellyba hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT stephenehawes hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT macoumbatoure hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT alisonkstarling hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT fatoutraore hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT fatimasall hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT stephenlcherne hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT joshuastern hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT kimgwong hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT paullu hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT moonkim hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT dananraugi hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT airinlam hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT jamesimullins hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT nancybkiviat hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica AT papasalifsowfortheuwdakarhiv2studygroup hiv2integrasevariationinintegraseinhibitornaiveadultsinsenegalwestafrica |